Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis

There are limited data investigating the epidemiology and resource utilization associated with parenteral prostacyclin use in children. We sought to examine national trends in treatment practices and resource utilization during prostacyclin initiation for pulmonary arterial hypertension (PAH) at children’s hospitals in the United States. Patients with PAH initiated on parenteral epoprostenol and treprostinil (2004–2014) were identified using a nationwide administrative database. Demographics, clinical characteristics, and resource utilization were compared between epoprostenol and treprostinil groups. Costs were indexed in 2014 US dollars. Among 1448 children admitted with a primary or secondary diagnosis of PAH, 280 (19%) were initiated on parenteral prostacyclins (epoprostenol n = 195 and treprostinil n = 85). Epoprostenol predominated early (97% of initiations in 2005); however, treprostinil predominated recently (52–67% of initiations/year). Children initiated on treprostinil had shorter ICU stays (1 [IQR = 0–4] vs. 4 [0–10] days, P  < 0.001), shorter total lengths of stay (4 [2–9] vs. 8 [4–18] days, P  = 0.001), and lower in‐hospital mortality (1 vs. 12%, P  = 0.001) with no difference in 30‐day (13 vs. 19%, P  = 0.19) or one‐year readmission rates (56 vs. 61%, P  = 0.41). Inpatient costs were lower for treprostinil initiation ($23,779 [11,830–39,535] vs. $32,976 [11,904–94,082], P  = 0.03), with a greater difference in the recent era (2009–2013). Though significant variation exists regarding prostacyclin use for PAH across US centers, prostacyclins are common among children with PAH. Treprostinil initiation has been increasing and is associated with less resource utilization and lower cost compared to epoprostenol initiation. Post‐discharge outcome data are needed to fully inform decision‐making about the relative benefits of parental prostacyclin drug choice.